Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.14.
Overvalued
The company’s latest PE is -0.41, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.74M shares, increasing 6.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 951.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.15.